Continuous veno-venous haemofiltration in the treatment of severe acute pancreatitis: 6-year experience  by Pupelis, G. et al.
ORIGINAL ARTICLE
Continuous veno-venous haemofiltration in the treatment of severe
acute pancreatitis: 6-year experience
G. PUPELIS1, H. PLAUDIS1, A. GRIGANE2, K. ZEIZA1 & G. PURMALIS1
1Department of Surgery and 2Department of Renal Replacement Therapy, Clinical Hospital ‘‘Gailezers’’, Riga, Latvia
Abstract
Background. Continuous veno-venous haemofiltration (CVVH) could be reasonable for attenuation of systemic
complications in severe acute pancreatitis (SAP). The aim of the study was implementation and feasibility assessment
of the CVVH in the treatment protocol of SAP. Patients and methods. CVVH was applied to 111 SAP patients during
20002005. APACHE II, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome
(MODS), serum lipase, C-reactive protein (CRP), complication rate and main outcomes were analysed comparing two
periods. Results. Overall, 39 patients corresponded to Balthazar grade E SAP and 72 patients to necrotizing SAP (NSAP),
with an average APACHE II score of 7 and 8.5, respectively, on admission. CVVH was started within 48 h in 82% of
patients. Duration of CVVH was significantly augmented in NSAP patients during the routine period, comprising 92 h (p
0.006). The clinical presentation of SIRS and MODS was similar in both periods, with more initial pulmonary dysfunctions
in NSAP (p0.048). Peripancreatic infection decreased in the routine period; surgical interventions were performed in
34.8% vs 72.4% of patients. Hospital stay comprised on average 15.9 days for grade E SAP and 29.4 days for NSAP in the
routine period, with overall mortality of 10.26% and 30.5%, respectively. Discussion. Application of CVVH in the treatment
protocol of SAP is obscure due to relative invasiveness, a poorly understood mechanism of action and scarce clinical
experience. We conclude that early pre-emptive application of CVVH is safe and feasible in the treatment of SAP. Duration
of the procedure seems to be essential. Randomized clinical trials are justified. Our results are in favour of clinical
application of CVVH in the treatment of SAP.
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Introduction
The clinical course of severe acute pancreatitis (SAP)
is well studied and two phases of the systemic
inflammatory response process are generally accepted
as typical for this dangerous condition [1]. Successful
treatment of systemic inflammatory response syn-
drome (SIRS), prophylaxis of early organ dysfunction
and prophylaxis of infection in the first phase of the
disease form the basis for good prognosis and positive
outcome [13]. The second clinical phase, in its most
severe forms  generally in cases with necrotizing sAP
(NSAP)  depends almost entirely on the presence of
infection. Effective treatment and prevention of in-
fection in the first phase, even in NSAP, to a great
extent is a guarantee of recovery and low rate of
complications. On the other hand, presence of infec-
tion raises the risk of repeated development of SIRS
and multiple organ dysfunction syndrome (MODS),
the main causes of morbidity and mortality in the
second phase. A conservative approach in the early
phase of SAP rather than an aggressive surgical
approach has proved to be more reasonable, due to
effective treatment modalities of modern critical care
[4]. At the same time, positive bacteriological culture
of the peripancreatic area with signs of repeated or
continuing ascending SIRS and progressive MODS
mandates surgical intervention mostly in the second
phase of disease [1]. Accordingly, effective initial
treatment should be oriented to faster recovery of
the organ perfusion and microcirculation, especially
the visceral microcirculation. This is the most im-
portant task considering that good visceral perfusion
is the main determinant of maintenance of safe bowel
barrier function, prevention of bacterial translocation
and prevention of peripancreatic infection [5]. Rapid
recovery of bowel function is mandatory for the
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initiation of early enteral feeding, another important
treatment modality for down-regulation of SIRS and
prevention of sepsis [6]. Effective modulation of SIRS
and organ support are the cornerstones of the con-
servative management of SAP. Prevention of septic
complications also includes the principle of applying
minimally invasive treatment modalities, to preserve
other organism barriers such as respiratory and
urinary tract mucosa and skin. The invasiveness,
however minimal, together with the risk of bleeding,
high costs and the not well-understood mechanism of
functioning are the main arguments against very wide
implementation of continuous veno-venous haemofil-
tration (CVVH) in the routine treatment protocol for
SAP [7]. Therefore the potential role of CVVH in the
treatment plan of SAP is still a matter of debate.
Positive results are available from experimental stu-
dies in animals [8]. Scarce clinical experience has
demonstrated positive treatment results after CVVH
in SAP patients; however, no definite guidelines
regarding the timing, duration and mode of CVVH
are available for this category of patients [9,10]. Since
1999, we have introduced clinical implementation of
CVVH in the treatment protocol of SAP. At the
present time, this procedure is routinely applied in our
hospital. We have not found any published reports
with similar experience in clinical application of
CVVH for the conservative treatment of SAP pa-
tients. The aim of this feasibility study is to share our
6-year experience with implementation of the CVVH
in the complex treatment protocol of SAP.
Patients and methods
SAP patients with Balthazar CTSI grade E and/or
necrotizing SAP in whom CVVH was applied as an
integral part of the treatment protocol were prospec-
tively enrolled between January 2000 and December
2005. SAP was classified according to Atlanta 1992
[11]. NSAP diagnosis was based on the clinical
picture supported by radiological evidence of pan-
creatic necrosis and/or involvement of the peripan-
creatic tissue in contrast-enhanced CT scan or proved
during surgical intervention. An additional criterion
for this group was maximal C-reactive protein (CRP)
level 200 mg/L. All patients were treated in the
intensive care unit (ICU). APACHE II scores were
calculated at admission and were used as initial
prognostic criteria. Symptoms of SIRS, organ dys-
function and incidence of MODS, dynamics of serum
lipase and CRP were recorded. The incidence of
septic complications was analysed considering the
primary and secondary types of peripancreatic infec-
tion. Primary infection was considered when applica-
tion of CVVH and conservative treatment failed to
prevent peripancreatic septic complications and the
source of infection was mainly the gastrointestinal
tract. Secondary infection was considered when con-
tamination by nosocomial flora was observed after
early surgical intervention. Sepsis was considered
when positive blood culture was obtained.
Haemofiltration was performed using Diapact
CRRT from B. Braun Co. or Fresenius Medical
Care Multifiltrate Machines, Germany. Synthetic
high volume membrane filters were used (surface
area 1.52.2 m2). Filter change was performed rou-
tinely once every 24 h or when filter clotting occurred.
Vascular access was obtained by one double or triple
line catheter inserted into the femoral or jugular vein.
Non-fractionated heparin was used for anticoagula-
tion, and the adequate dosage was individually
adjusted to APTL. The procedure was provided
without heparin or with low heparin dose whenever
possible. The substitution fluid was infused at the rate
of 1000 ml/h in pre-diluted or post-diluted manner,
comprising 2435 L of total substitute in 24 h. The
blood flow ranged within 50200 ml/min. Ultrafiltra-
tion rate was controlled depending on diuresis and
fluid balance. Haemodiafiltration was provided in
accordance with individual indications.
The main indications for application of CVVH were
progression of SIRS, abdominal compartment syn-
drome (IAP25 cm/H2O) and MODS despite com-
plex initial intensive therapy within 2448 h.
Organ failure was defined according to the recom-
mendations of the Consensus Conference of Amer-
ican College of Chest Physicians/Society of Critical
Care Medicine in 1991 [12,13]. SIRS was diagnosed
if two or more of the following conditions were
detected: (a) temperature above 388C or below
368C, (b) heart rate above 90 beats/min, (c) respira-
tory rate above 20 breaths/min, or arterial carbon
dioxide tension below 32 mmHg, and (d) white blood
cell count above 12 000/mm3 or below 4000/mm3, or
immature (band) forms accounting for more than
10% of neutrophils present [14]. MODS was diag-
nosed if dysfunction of more than one organ was
detected, requiring intervention to maintain home-
ostasis. SOFA score was calculated for daily assess-
ment of the dynamics of organ dysfunction [13].
Radiological evidence of basal atelectasis, pneumonia
or pleural effusion was recorded as pulmonary com-
plications. Pulmonary dysfunction was classified ac-
cording to SOFA score data. Acidosis was diagnosed
when pH in the peripheral blood was B7.2. Compli-
cation rate, ICU, hospital stay and main outcomes
were recorded and analysed in the learning curve
period and the routine period (the first and the second
3-year periods). CVVH procedure for SAP patients
was accepted by the hospital administration and the
local ethics commission, and patients were informed
about the procedure and the associated risks and
complications.
Statistical comparison was performed with paired
samples t test. All clinical data were expressed as
average9standard deviation. Correlation data were
calculated using Pearson’s and Spearman’s correlation
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test. Data analysis was performed with SPSS software
version 8.0 (SPSS Inc.).
Results
Patient characteristics and severity of disease
A total of 246 patients with SAP were treated in our
hospital during the last 6 years. CVVH was applied in
111 SAP patients as an integral part of the treatment
protocol. The male to female ratio was 89:22. Alcohol
and gallstones were the major aetiological factors. Of
all patients, 39 suffered acute oedematous pancreatitis
with multiple localizations of the inflammatory exu-
dates complying with Balthazar CTSI grade E criteria.
Radiological or intraoperative evidence of pancreatic
necrosis and/or involvement of the peripancreatic
tissue in parallel with CRP 200 mg/L were observed
in 72 patients who were classified as NSAP. All
patients received initial conservative treatment includ-
ing organ support, active recovery of the tissue
perfusion and reduction of the fluid sequestration in
the third space by means of isovolaemic haemodilution
with adequate colloid/crystalloid infusions.
The average APACHE II score at admission was
795.4 points for grade E SAP and 8.595.3 points for
NSAP. Relatively low APACHE II scores at admission
were partially due to the prevalence of young male
alcohol abusers. The clinical course of SAP was
characterized by a similar incidence of SIRS and
MODS in both clinical groups in the first phase of the
disease, when evaluating the whole period of the
study. However, the overall incidence of pulmonary
dysfunction/pulmonary complications and metabolic
acidosis was significantly higher in NSAP (Table I).
A more detailed comparison of the clinical data in
the learning period and the routine period did not
show significant differences in either clinical group
except more frequent development of encephalopa-
thies among NSAP patients in the routine period (p
0.047) (Table II).
Timing of CVVH
An overall increase in the number of patients who
received CVVH was characteristic of the routine
period for both clinical groups. Commencement of
the CVVH procedure was started within 48 h from
admission in 82% of patients. Duration of the
procedure was optimized during the learning period
approaching roughly 48 h and more. Longer proce-
dures were applied in NSAP patients when the whole
study period was evaluated; however, this did not
reach statistical significance. The average duration of
CVVH was prolonged in both clinical groups, as
experience with the procedure grew. Significant in-
crease in the duration of CVVH was evident in NSAP
patients when comparing the learning and the routine
periods, comprising an average of 51.9925.3 and
92970.4 h, respectively (p0.006) (Table II).
Efficacy of CVVH
More effective recovery of the organ function in all
surviving patients was observed in the routine period
when the CVVH procedure lasted longer compared
with the learning period. A statistically significant
difference in SOFA score was evident on day 7 after
admission (p0.04) (Figure 1).
The duration of CVVH was 548 h in 49 patients
and 48 hours in 62 patients. The longer CVVH
procedure (48 h) was provided in patients with a
significantly higher number of initial pulmonary
dysfunctions and pulmonary complications. At the
same time, longer procedures were associated with
lower mortality rate (p0.038) (Table III).
Laboratory data
Laboratory data were in concordance with the clinical
course and the signs of systemic inflammatory re-
sponse. Overall dynamics of CRP and serum lipase
activity showed similar patterns in both clinical groups
(Figures 2 and 3). Furthermore, a very similar pattern
of CRP and serum lipase activity after application of
CVVH was observed in the learning and the routine
period, with a strong tendency towards normalization
on average at day 7 from admission (Figures 4 and 5).
A decrease in CRP activity positively interrelated with
regression of organ dysfunction (r0.286, p
0.002) (Figure 6).
Infection, surgical interventions and outcomes
The overall incidence of peripancreatic infection
decreased from 37.9% during the learning curve to
23.3% in the routine period. This was achieved by a
more conservative approach, and consequently the
number of surgical interventions dropped from 72.4%
to 34.8%. All surgical interventions, except one,
were done in NSAP patients. Primary peripancreatic
Table I. Clinical presentation of SAP during all study periods.
Parameter Grade E SAP NSAP p value
Patients (n ) 39 72 
APACHE II (average
points)
7 8.49 NS
SIRS (no. of cases) 35 69 NS
MODS (no. of cases) 32 70 NS
Metabolic acidosis
(no. of cases)
2 13 0.032
Renal dysfunction
(no. of cases)
15 31 NS
Pulmonary dysfunction
(no. of cases)
15 51 0.048
Atelectasis (no. of cases) 0 8 0.006
Pneumonia
(no. of cases)
2 24 0.006
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infection was the indication for surgical intervention
in 10 NSAP patients after the second week from
admission, on average 17.6911.9 days after the
commencement of CVVH.
Secondary peripancreatic infection was observed
similarly in 10 patients who were operated early in the
course, mostly due to obscure diagnosis or uncertain
progression of MODS, on average 2.393.5 days after
application of CVVH. All secondarily infected patients
received CVVH before and after the surgical interven-
tion. Overall mortality in infected patients was 25%
(five cases). Positive bacteriological blood cultures
were observed in only six NSAP patients, with similar
incidence regarding the duration of CVVH. The
growing experience with the application of CVVH
procedure in the treatment protocol of SAP resulted in
shorter ICU and hospital stays, comparing the learn-
ing and the routine periods; however, this did not
reach a statistically significant difference (Table IV).
The average length of ICU stay for the whole study
period was 794.7 days for grade E SAP and 15.469
12.1 days for NSAP patients. Correspondingly, hos-
pital stay comprised 16.4910.5 and 33.5927.2 days,
respectively. Finally, routine application of CVVH
was associated with 10.26% (4 cases in grade E SAP)
and 30.5% (22 cases in NSAP) mortality rate (p
0.01). Application of CVVH for 48 h resulted in a
significantly lower mortality rate, compared with a
shorter application of the procedure (p0.038).
Discussion
The clinical course of SAP with ascending SIRS and
development of organ dysfunction is recognized and
described with delineation of two clinical phases [1].
According to the current recommendations, successful
treatment is related to a prompt recognition of the
most severe forms, with emphasis on necrotizing
pancreatitis. A general agreement exists that early
adequate fluid and electrolyte restitution, organ sup-
port and infection prophylaxis are the cornerstones of
the conservative treatment in the first phase of the
disease. Proven presence of the peripancreatic infec-
tion mandates surgical intervention most frequently in
the second phase of the disease, mainly in NSAP
patients [14]. Effective intravascular and extravascu-
lar fluid balance is crucial for recovery of the organ
perfusion and microcirculation, being severely im-
paired in SAP. The magnitude of the impaired visceral
perfusion is of utmost importance for further prog-
nosis, as it is the key factor for bowel barrier integrity
and the main condition for prevention of bacterial
translocation [15]. Early enteral feeding, another
important treatment modality for down- regulation
of SIRS and prevention of sepsis [6], is not applicable
when bowel function is severely impaired. Increase of
the intra-abdominal pressure (IAP) and development
of the abdominal compartment syndrome as a result of
Table II. Clinical course of SAP and duration of the CVVH.
NSAP Grade E SAP
Clinical group Learning period Routine period Learning period Routine period
Patients (n ) 29 43 10 29
APACHE II (points) 7,9 9 6 7.55
MODS (no. of cases) 28 42 8 24
Pulmonary dysfunction (no. of cases) 18 33 1 14
Pulmonary complications (no. of cases) 27 48 1 17
Sepsis (no. of cases) 2 4 0 0
Encephalopathy (no. of cases) 6 20* 3 12
Duration of CVVH (h) 51.9 92.0** 42.5 70.9
Duration of CVVH overall (h) 75.8 63.6
*p0.047; **p0.006.
SOFA score
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Figure 1. Regression of the organ dysfunction comparing the
learning curve and the routine period in all surviving patients.
Table III. Clinical course in relation to the duration of the CVVH
procedure.
Parameter
CVVH
B48 h
CVVH
48 h p value
Patients (n ) 49 62 NS
CVVH application period (h) 30,3 103,8 B0.05
APACHE II (points) 8,77 7,54 NS
SIRS (no. of cases) 45 59 NS
MODS (no. of cases) 42 60 NS
Pulmonary dysfunction
(no. of cases)
23 43 0.006
Pleural effusion (no. of cases) 16 41 0.001
Renal dysfunction
(no. of cases)
17 29 NS
Death (n ) 16 10 0.038
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the huge extravascular fluid loss and visceral oedema
further deteriorates visceral perfusion. This scenario is
more often seen in obese patients and/or in cases when
initial large volume fluid replacement was provided
with crystalloids only. Then fluid retention in the
extravascular compartment, or the so-called ‘third
space’, is inevitable due to increased vascular perme-
ability as a consequence of SIRS. Dyspnoea and
oligoanuria are the most characteristic clinical signs
in this condition. It was often the case when our
patients with SAP rapidly deteriorated after initial 48 h
therapy. Transfers to the ICU frequently were too late
for prevention and successful treatment of MODS.
Unfortunately, clinical deterioration, especially in
necrotizing forms, mandated surgeons to intervene
earlier than generally recommended, even after com-
mencement of the organ support therapy and im-
provement of the microcirculation. At the same time,
even when it was possible to prolong conservative
management into the second week, the rate of
peripancreatic infection was remarkably high in this
category of patients. Severity of the disease in SAP
patients is not directly related solely to the extent of
necrosis, but rather to individual systemic inflamma-
tory response. This individual systemic inflammatory
response could also be marked in patients with grade E
SAP and associated with early development of organ
dysfunction and abdominal compartment syndrome.
In 1999 we reconsidered our treatment strategy.
The main breakthrough was upgrade of the duty staff
regarding admission criteria for early recognition of
SAP. All patients with suspected SAP were consulted
by an intensive care specialist and directly admitted to
the ICU according to indications. Implementation of
the early enteral feeding directed our attention to-
wards the problem of elevated IAP and the finding
that enteral feeding is not possible when IAP ap-
proaches or exceeds 25 cmH2O [16]. Unfortunately
at that time conservative treatment was not effective
enough for prompt reduction of the sustained increase
of the IAP. Therapy results improved considerably
when the Department of Renal Replacement Therapy
came forward with the recommendation to try CVVH
in the treatment of SAP. The first successful series
with CVVH prompted formulation of more definite
indications for the application of the procedure. The
valuable observation that an early application of
CVVH was effective in reduction of the severely
increased IAP pushed us to continue this strategy
and follow a more conservative approach. The com-
parison of two patient groups was done to compare
the overall outcomes in association with application of
the CVVH in two different periods. After the learning
period, certain experience was collected. The impor-
tant finding was a very similar pattern of down-
regulation of SIRS and recovery of the organ function
in both groups when improvement was achieved.
Another important finding was a similar decrease in
the number of occurrences of surgical sepsis when
experience was collected. We did not compare CVVH
with other treatment modalities, although our experi-
ence demonstrates that CVVH can be a safe addi-
tional treatment option for a basic SAP management
protocol and results are improving with more experi-
ence in the application of the procedure. The mar-
ginal difference in CRP on day 7 proves a uniform
pattern of the decrease of the systemic inflammatory
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Figure 3. Activity of serum lipase in clinical groups.
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Figure 5. CRP and lipase activity in routine period.
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Figure 2. Dynamics of CRP in clinical groups in whole treatment
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reaction regardless of whether the patient suffered
from necrotizing or grade E SAP. This is evident in all
study periods and proves the safety of CVVH. We do
not state that this is only due to successful application
of the CVVH; however, certainly this is in association
with this procedure.
According to the available reports from the litera-
ture, application of CVVH is not well recognized in
patients with SAP, although it is recommended for the
treatment of severe sepsis [17,18]. Disturbances of the
microcirculation, increased vascular permeability and
insufficient perfusion/oxygenation of the end organ
are claimed to be the central pathophysiologic event in
the sepsis-like systemic inflammatory response, char-
acteristic also for SAP [19,20]. The concept of the
application of CVVH is based on the hypothesis that
elimination of numerous proinflammatory cytokines
in SIRS and anti-inflammatory cytokines in counter
anti-inflammatory response syndrome (CARS) can
provide equilibrated immune response. This concept
is known as the hypothesis of ‘cutting the peaks’ [18].
However, the question remains whether elimination of
the cytokines from the bloodstream is the main
impacting factor for the modulation of SIRS, because
changes in the interstitial and tissue compartment are
equally clinically important. According to the Honore´
concept, removal of the mediators and pro-mediators
at the interstitial and tissue levels secondary to
removal from the blood compartment could block
basic pathways and stop further tissue damage and
organ injury [21,22]. It seems that early application of
CVVH can modulate SIRS and consequently dimin-
ish incidence of systemic complications. Our data are
not sufficient to draw firm conclusions regarding the
true mechanisms of the action underlying the positive
effect of CVVH application in SAP patients. Initially,
treatment of the renal dysfunction was the basic
concern. Afterwards, reduction of the third space
and state of hyperhydration were identified as addi-
tional indications. Effective decrease and normaliza-
tion of the IAP, reduction of the peripancreatic
exudation in parallel with recovery of the pulmonary,
gastrointestinal and kidney function after application
of CVVH validated this approach [23]. A pre-emptive
strategy was favoured for MODS control. Early
commencement of CVVH and prolongation of the
procedure over a 48 h period resulted in significantly
reduced mortality. At the same time, the degree of the
renal dysfunction corresponded to ‘R’ (risk of dys-
function) and ‘I’ (injury) according to RIFLE criteria
[24] in the majority of patients.
Our data comply with the reported existence of the
so-called ‘therapeutic window’ within 4872 h from
the onset of SAP when acute inflammatory response
reaches maximum due to peak output of cytokines
[25]. However, according to our observations, the
point of reference could be the start of adequate
treatment in most cases, rather than the time of the
onset of disease. Average highest values of the SOFA
score and CRP in our patients were observed around
the third day from admission and then declined. This
was not in parallel with the time from the onset of the
disease. Considering the fact that the majority of
patients received CVVH within 48 h from admission,
presumably effective early application of the CVVH
can give an additional chance to patients with 48 h
anamnesis. It seems that an important condition is an
appropriate duration of the procedure rather than the
high volume mode recommended by some authors in
severe sepsis [26,27], if it is applied in a pre-emptive
way. We did not observe serious procedure-associated
complications, which is in parallel with the results
from other studies [28]. Despite some invasiveness of
the procedure, the overall rate of infection decreased
in common with the number of surgical interventions,
and final outcomes are in the range of internationally
reported data [2931].
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Figure 6. Positive interrelation of CRP and SOFA score.
Table IV. Septic complications, surgical interventions and outcomes.
Grade E SAP (n39) NSAP (n72)
Parameter Learning period Routine period Learning period Routine period p value
Positive blood culture (no. of cases) 0 0 3 3 0.023
ICU stay (days) 6.1 7.34 18.6 13.3 NS
Hospital stay (days) 18 15.9 38.7 29.4 NS
Mortality (n /%) 2/20 1/6.9 10/34.5 12/27.9 NS
Overall mortality 10.26% (4 cases) 30.5% (22 cases) 0.01
Overall hospital stay (days) 16.4 33.5 B0.05
Overall ICU stay (days) 7 15.46 B0.05
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Conclusion
Early pre-emptive application of CVVH is a safe and
feasible therapeutic modality in the treatment proto-
col of SAP. Adequate duration of the procedure seems
to be essential. Further randomized clinical trials are
justified for better understanding of the mechanism of
action and efficacy of the CVVH, comparing to other
conservative treatment modalities.
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